SWOG clinical trial number
CTSU/EA8141

A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma

Closed
Phase
Abbreviated Title
Pro Phase II Neo Sys Chem Followed by Extir Surg for HG UTCC
Activated
04/10/2015
Participants
CTSU

Research committees

Genitourinary Cancer

Treatment

Cisplatin Carboplatin Doxorubicin Gemcitabine hydrochloride Methotrexate Vinblastine Pegfilgrastim

Publication Information Expand/Collapse

2020

Results of a Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma

V Margulis;M Puliigandla;E Trabulsi;E Plimack;E Kessler;S Matin;G Godoy;A Alva;N Hahn;M Carducci;J Hoffman-Censits Journal of Urology Apr;203(4):690-698; Nov 8:101097JU0000000000000644.[Epub ahead of print]

PMid: PMID31702432

2018

Phase II trial of neoadjuvant chemotherapy followed by extirpative surgery for patients with high grade upper tract urothelial carcinoma (HG UTUC): results from ECOG-ACRIN 8141

J Hoffman-Censits;M Puligandla;E Trabulski;E Plimack;E Kessler;S Matin;G Godoy;A Alva;N Hahn;M Carducci;V Margulis Journal of Urology Vol. 199, No. 4S, Supplement, LBA26, p. e1166; American Urological Association Annual Meeting 2018

Other Clinical Trials

SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
SWOG Clinical Trial Number
CTSU/A031901